Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model

Basit Öğe Kaydı
dc.contributor.authorAkman, Levent
dc.contributor.authorSahin, Gulnaz
dc.contributor.authorErbas, Oytun
dc.contributor.authorAktug, Huseyin
dc.contributor.authorAkdogan, Aysin
dc.contributor.authorGoker, Ege Nazan Tavmergen
dc.contributor.authorTaskiran, Dilek
dc.contributor.authorTavmergen, Erol
dc.date.accessioned2019-10-27T22:27:10Z
dc.date.available2019-10-27T22:27:10Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractOvarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication that can occur during assisted reproductive techniques. The aim of this study is to investigate the effects of the leukotriene receptor antagonist (montelukast) treatment in prevention of OHSS and compare to cabergoline treatment. Twenty-four immature female Wistar rats were assigned to four groups. Group 1 was the control group. In the rennaning three groups, OHSS was induced through ovarian stimulation with gonadotropins. No treatment was given to Group 2. Group 3 was administered a low-dose 100 mg/kg cabergoline treatment and Group 4 was received 20 mg/kg montelukast. Body weight, ovarian weight, vasculary permability (VP), peritoneal fluid vascular endothelial growth factor (VEGF) values and VEGF immune-expression were compared between the groups. Both cabergoline and montelukast prevented progression of OHSS compared to the OHSS group. Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group. In conclusion, montelukast is an effective option for prevention of OHSS, as well as cabergoline. Montelukast may be a new treatment option to prevent and control the OHSS.en_US
dc.identifier.doi10.3109/09513590.2014.1000849en_US
dc.identifier.endpage373en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue5en_US
dc.identifier.pmid25599748en_US
dc.identifier.startpage369en_US
dc.identifier.urihttps://doi.org/10.3109/09513590.2014.1000849
dc.identifier.urihttps://hdl.handle.net/11454/50591
dc.identifier.volume31en_US
dc.identifier.wosWOS:000358972300007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCabergolineen_US
dc.subjectmontelukasten_US
dc.subjectovarian hyperstimulation syndromeen_US
dc.subjectrat modelen_US
dc.titleComparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu